Xtant Medical
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Xtant Medical and other ETFs, options, and stocks.About XTNT
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix.
CEOSean E. Browne
CEOSean E. Browne
Employees232
Employees232
HeadquartersBelgrade, Montana
HeadquartersBelgrade, Montana
Founded2006
Founded2006
Employees232
Employees232
XTNT Key Statistics
Market cap85.71M
Market cap85.71M
Price-Earnings ratio59.83
Price-Earnings ratio59.83
Dividend yield—
Dividend yield—
Average volume171.54K
Average volume171.54K
High today$0.65
High today$0.65
Low today$0.61
Low today$0.61
Open price$0.65
Open price$0.65
Volume114.99K
Volume114.99K
52 Week high$0.95
52 Week high$0.95
52 Week low$0.331
52 Week low$0.331
Stock Snapshot
Xtant Medical(XTNT) stock is priced at $0.61, giving the company a market capitalization of 85.71M. It carries a P/E multiple of 59.83.
On 2025-12-05, Xtant Medical(XTNT) stock moved within a range of $0.61 to $0.65. With shares now at $0.61, the stock is trading +0.5% above its intraday low and -5.7% below the session's peak.
Trading activity shows a volume of 114.99K, compared to an average daily volume of 171.54K.
The stock's 52-week range extends from a low of $0.33 to a high of $0.95.
The stock's 52-week range extends from a low of $0.33 to a high of $0.95.
XTNT News
TipRanks 2d
Xtant Medical Sells Assets to Companion SpineTipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...
People also own
Based on the portfolios of people who own XTNT. This list is generated using Robinhood data, and it’s not a recommendation.